Jun 27, 2026
15 MIN READ

What Qualifies You for Ozempic for Weight Loss?

Semaglutide eligibility goes beyond BMI alone. PlexusDx breaks down the clinical criteria that determine whether you're a candidate for this GLP-1 therapy, and how to access it without insurance.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jun 27, 2026
15 MIN READ

what qualifies you for ozempic for weight loss? — PlexusDx GLP-1 education

Last reviewed: June 28, 2026

Last updated: June 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide has transformed weight loss for millions, with clinical trials showing average weight reductions of 15% over 68 weeks. But not everyone qualifies under the same criteria. PlexusDx explains the medical benchmarks that determine eligibility, how to assess your own candidacy, and what happens next if you meet them.

BMI Thresholds and Weight Loss Criteria for Semaglutide

The FDA-approved weight loss indication for semaglutide requires a BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² with at least one weight-related health condition. A BMI of 30 corresponds roughly to 221 pounds at 5'10". However, PlexusDx recognizes that BMI is a screening tool, not a diagnosis—many patients below these thresholds still benefit from treatment based on metabolic and genetic factors.

Beyond BMI, physicians evaluate your weight trajectory, previous dieting attempts, and metabolic markers like fasting glucose and insulin resistance. Patients who have struggled with traditional diet and exercise alone, or who regain weight quickly after previous loss, often show strong candidacy even if their current BMI is borderline. This individualized assessment helps identify who will respond best to semaglutide therapy.

Weight loss medications work best when combined with lifestyle modification. PlexusDx candidates typically commit to dietary improvements and increased physical activity while on treatment. Your starting dose may need to increase over time to reach your therapeutic level, but your monthly price stays the same—starting at $149/mo for compounded semaglutide injection across all commitment tiers.

Medical Conditions That Support Semaglutide Eligibility

Type 2 diabetes, hypertension, cardiovascular disease, and sleep apnea are common weight-related conditions that strengthen the case for semaglutide candidacy. Even pre-diabetic glucose levels (fasting glucose 100–125 mg/dL) qualify as a weight-related comorbidity. Patients with these diagnoses often experience dual benefits: weight loss plus improved metabolic control of their underlying condition.

Polycystic ovary syndrome (PCOS), fatty liver disease, and chronic inflammatory conditions also support eligibility, since semaglutide improves insulin sensitivity and reduces systemic inflammation. If you have any diagnosed metabolic or cardiovascular condition alongside excess weight, you likely meet clinical criteria. A PlexusDx provider review can confirm whether your specific health profile qualifies.

The presence of comorbidities is powerful because it demonstrates that your weight is actively harming your health. Insurance companies and clinical guidelines both recognize this: a patient with hypertension and a BMI of 27 may qualify just as readily as a patient with a BMI of 35 and no other conditions. PlexusDx serves all 50 states with no insurance requirement, so you don't need prior authorization or employer coverage to begin.

Medications and Health History That Affect Semaglutide Candidacy

Current medications rarely disqualify you from semaglutide, but certain combinations require closer monitoring. If you take insulin or other diabetes medications, your doses may need adjustment downward as semaglutide lowers blood glucose. Blood pressure medications should be reviewed, since weight loss itself can lower blood pressure over time. PlexusDx provider assessments always include a full medication review to prevent unsafe interactions.

A personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type 2 (MEN2) is a contraindication—semaglutide carries a black-box warning for these conditions because animal studies suggested thyroid C-cell tumors. Severe gastroparesis (stomach paralysis) is another relative contraindication, since GLP-1 agonists slow gastric emptying further. Acute pancreatitis history requires careful evaluation, though past pancreatitis is not absolute disqualification.

Pregnancy and breastfeeding require discontinuation of semaglutide. Women of reproductive age should use contraception while on therapy and plan to stop treatment at least 2 months before attempting conception. PlexusDx evaluates all these factors during the provider consultation to ensure safe, appropriate candidacy.

How Genetic Factors Shape Your Semaglutide Response

Not everyone responds equally to semaglutide. Genetic variation in GLP-1 receptor signaling, appetite regulation, and metabolic pathways influences both efficacy and tolerability. The PlexusDx Precision Peptide Genetic Test identifies key variants—including GLP1R rs6923761 and GIPR rs1800437—that predict how your body processes and responds to semaglutide therapy. This test is available as a $99 add-on after your first month of treatment.

Patients carrying certain genetic variants may achieve greater weight loss with semaglutide, while others show stronger responses to combination therapy like PlexusDx's GLP-Squared protocol (semaglutide plus tirzepatide). FTO rs9939609 and MC4R rs17782313 variants also correlate with baseline appetite regulation and metabolic capacity. By mapping 14 pathways and 49 peptides, PlexusDx provides 150+ genetic insights that personalize your treatment plan beyond standard eligibility criteria.

Genetic testing does not determine eligibility—it refines it. You qualify for semaglutide based on BMI and health history, but your genetic profile helps explain why you might need dose adjustments, combination therapy, or a switch to a different compound. This precision approach removes guesswork and accelerates your path to effective weight loss.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Do I need a BMI of 30 to qualify for semaglutide with PlexusDx?

No. FDA criteria allow semaglutide at BMI 30+, or BMI 27+ with a weight-related condition like hypertension or prediabetes. PlexusDx providers assess your individual health profile, not just BMI, so borderline cases are often approved based on metabolic markers and comorbidities.

Will semaglutide work for me if I have type 2 diabetes?

Yes. Semaglutide is FDA-approved for both weight loss and diabetes management. Patients with type 2 diabetes often see excellent weight loss (average 10–15%) alongside improved blood sugar control. Your diabetes medications may need adjustment, which PlexusDx providers monitor closely.

How much does PlexusDx semaglutide cost, and do I need insurance?

Compounded semaglutide injection starts at $149/month and is HSA/FSA eligible. PlexusDx serves all 50 states with no insurance requirement and no membership fee. Your dose may need to go up as you progress through treatment, but your price stays the same.

Are there any medical conditions that disqualify me from semaglutide?

Personal or family history of medullary thyroid cancer and multiple endocrine neoplasia type 2 are absolute contraindications. Severe gastroparesis and a history of acute pancreatitis require careful evaluation. PlexusDx providers review your full medical history during qualification to ensure safety.

How can genetic testing help me qualify for or optimize semaglutide?

The PlexusDx Precision Peptide Genetic Test ($99 add-on) identifies variants in GLP1R, GIPR, FTO, and MC4R that predict your response to semaglutide. This information helps confirm candidacy, predict dose needs, and determine whether combination therapy might work better for your unique peptide pathways.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves